Spectrum: Local Antimicrobial Stewardship, for CHEO-OCTC

MetroNIDAZOLE

C. diff Risk

Low

Oral Bioavailability

NA

Approximate Cost

<$1/day (Oral)

Spectrum Of Activity

General Spectrum of Activity

Spectrum Of Activity

Dosing

Pediatric

Neonatal

General Information

Drug Monitoring

Drug Monitoring

Neurologic side effects including peripheral, optic neuropathy, aseptic meningitis, encephalopathy, reversible cerebellar lesions

First Line Indications

First Line Indications

  • Treatment of C. difficile colitis

  • Treatment of infections or abscesses where anaerobes are major pathogens in combination with another agent for aerobic bacteria

Oral Liquids

Oral Liquids

Concentration: 50 mg/mL

Taste: Unpleasant taste

Not all strengths of oral liquids are listed nor be available on the CHEO Formulary

Tablet/Capsule Strengths

Tablet/Capsule Strengths
  • 250 mg

Tablets or capsules are preferred especially over an unpleasant tasting oral liquid.

Not all strengths of oral tablets/capsules are listed and they are not all available on the CHEO Formulary.